Compare AMRC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | PCRX |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.0B |
| IPO Year | 2010 | 2010 |
| Metric | AMRC | PCRX |
|---|---|---|
| Price | $26.17 | $22.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $37.88 | $37.60 |
| AVG Volume (30 Days) | 416.0K | ★ 765.8K |
| Earning Date | 03-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 0.49 | 0.16 |
| Revenue | ★ $1,769,928,000.00 | $541,533,000.00 |
| Revenue This Year | $10.29 | $9.77 |
| Revenue Next Year | $10.42 | $9.71 |
| P/E Ratio | ★ $54.47 | $137.44 |
| Revenue Growth | ★ 28.76 | 26.04 |
| 52 Week Low | $8.49 | $18.80 |
| 52 Week High | $44.93 | $27.99 |
| Indicator | AMRC | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 50.84 |
| Support Level | $23.77 | $20.41 |
| Resistance Level | $31.12 | $23.82 |
| Average True Range (ATR) | 1.60 | 1.05 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 24.25 | 50.88 |
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.